| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
ATHA (ATHA) has 13 insiders with recent SEC Form 4 filings, including 0 buys and 10 sells. ATHA is classified in the Biotechnology industry within the Health Care sector.
| Role | Insider | Shares | Value | 30d |
|---|---|---|---|---|
| 10% | 329.8K | $2.09M | - | |
| CEO | 40.8K | $280.9K | - | |
| Dir | 20.9K | - | - | |
| Dir | 20.9K | - | - | |
| Dir | 20.9K | - | - |
Buys and sells only
| Date | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|
| Jan 2, 2025 | San Martin Javier65 | Chief Medical Officer | Sale+OE | 10,826 | $0.56 | $6,083.13 | -23.2% | |
| Jan 2, 2025 | Litton Mark James | President And CEO | Sale+OE | 25,107 | $0.56 | $14,107.62 | -9.4% | |
| Jan 2, 2025 | Church Kevin | Chief Scientific Officer | Sale+OE | 8,510 | $0.56 | $4,781.77 | -6.1% | |
| Jan 2, 2025 | Renninger Robert | VP Of Finance | Sale+OE | 2,881 | $0.56 | $1,618.83 | -3.1% | |
| Jan 2, 2025 | Worthington Mark | General Counsel And CCO | Sale+OE | 8,510 | $0.56 | $4,781.77 | -9.2% | |
| Sep 5, 2024 | Gengos Andrew67 | CFO And Chief Business Officer | Sell | 1,272 | $0.57 | $719.95 | -1.3% | |
| Sep 5, 2024 | Lenington Rachel | COO And Cdo | Sell | 2,525 | $0.57 | $1,429.15 | -10.8% | |
| Sep 5, 2024 | Church Kevin | Chief Scientific Officer | Sell | 2,525 | $0.57 | $1,429.15 | -2.7% | |
| Sep 5, 2024 | Worthington Mark | General Counsel | Sell | 2,525 | $0.57 | $1,429.15 | -4.6% | |
| Sep 5, 2024 | Litton Mark James | President And CEO | Sell | 5,032 | $0.57 | $2,848.11 | -3.1% |